- Home
- HHS vs CALC Comparison
HHS vs CALC Comparison
Compare HHS & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- CALC
- Stock Information
- Founded
- HHS 1923
- CALC 2011
- Country
- HHS United States
- CALC United States
- Employees
- HHS N/A
- CALC N/A
- Industry
- HHS Advertising
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- HHS Consumer Discretionary
- CALC Health Care
- Exchange
- HHS Nasdaq
- CALC Nasdaq
- Market Cap
- HHS 30.3M
- CALC 22.9M
- IPO Year
- HHS N/A
- CALC N/A
- Fundamental
- Price
- HHS $4.03
- CALC $2.13
- Analyst Decision
- HHS
- CALC Strong Buy
- Analyst Count
- HHS 0
- CALC 2
- Target Price
- HHS N/A
- CALC $14.50
- AVG Volume (30 Days)
- HHS 31.2K
- CALC 38.7K
- Earning Date
- HHS 08-07-2025
- CALC 08-11-2025
- Dividend Yield
- HHS N/A
- CALC N/A
- EPS Growth
- HHS N/A
- CALC N/A
- EPS
- HHS N/A
- CALC N/A
- Revenue
- HHS $181,355,000.00
- CALC N/A
- Revenue This Year
- HHS $6.54
- CALC N/A
- Revenue Next Year
- HHS N/A
- CALC N/A
- P/E Ratio
- HHS N/A
- CALC N/A
- Revenue Growth
- HHS N/A
- CALC N/A
- 52 Week Low
- HHS $3.24
- CALC $1.42
- 52 Week High
- HHS $8.80
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- HHS 40.53
- CALC 48.14
- Support Level
- HHS $3.61
- CALC $1.59
- Resistance Level
- HHS $4.05
- CALC $1.69
- Average True Range (ATR)
- HHS 0.57
- CALC 0.15
- MACD
- HHS 0.01
- CALC 0.01
- Stochastic Oscillator
- HHS 24.19
- CALC 46.51
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.